Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial

Nicole DeFeudis

Editor

When Idera Pharmaceuticals flunked a Phase III melanoma trial with its Toll-like receptor 9 agonist tilsotolimod back in March, executives clung to the hope …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

Post-Hoc: Pharma CEOs' alternative reality with Trump

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

FDA lifts hold on Entrada's Duchenne drug after two years

Sanofi, Teva bolster case for IBD drug with Phase 2 data, despite potential competition

How AI can address ongoing challenges in the life sciences industry

Idera Phar­ma­ceu­ti­cal­s' stock tanks af­ter Ab­b­Vie cuts en­roll­ment ear­ly in a PhIb tri­al

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Idera Pharmaceuticals' stock tanks after AbbVie cuts enrollment early in a PhIb trial